Keyword: Bristol-Myers Squibb
AbbVie inked a deal with the Medicines Patent Pool to boost access to hep C drug Mavyret in nearly 100 low- and middle-income countries and territories.
Merck just advanced the Keytruda-Opdivo immuno-oncology rivalry into a brand-new arena.
Less than five months after posting positive top-line data, Bristol-Myers Squibb and AbbVie have scored a new combo win for Empliciti.
On Bristol-Myers Squibb’s Thursday third-quarter conference call, executives plunged right into investors' doubts.
There’s no denying Bristol-Myers’ Opdivo had a tough week. But the way one analyst sees it, investors are overreacting.
Bristol-Myers presented a raft of results for its Opdivo-Yervoy combo at ESMO, but results it didn’t present stole the weekend spotlight.
BMS is looking to push its Opdivo-Yervoy combo further into colorectal cancer, and with new phase 2 data, it just might be able to.